ALK-positive Non-small Cell Lung Cancer Clinical Trials

20 clinical trials for ALK-positive Non-small Cell Lung Cancer across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC — RECRUITING · PHASE1
• Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib — RECRUITING
• Patient-centered, Optimal Integration of Survivorship and Palliative Care — RECRUITING · NA
• Standard dosed alectinib versus Therageutic Drug Monitoring guided alectinib dosing: The Adapt Alec trial — RECRUITING · PHASE4
• ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study — RECRUITING
• Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients — RECRUITING
• Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC — RECRUITING · PHASE2
• Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors — OTHER
• Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC — NOT_YET_RECRUITING · PHASE2
• Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms — ACTIVE_NOT_RECRUITING · PHASE2
• AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer — NOT_YET_RECRUITING · PHASE1
• A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment — ACTIVE_NOT_RECRUITING
• A multicenter single-arm phase II interventional study to evaluate the activity and safety of the combination of Platinum-Pemetrexed based chemotherapy plus Lorlatinib in ALK positive Non-Small Cell Lung Cancer (NSCLC) with exclusively extracranial disease progression on Lorlatinib — TERMINATED · PHASE2
• Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study — NOT_YET_RECRUITING · PHASE4
• A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis — OTHER
• Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib — TERMINATED · PHASE2
• Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients — COMPLETED
• Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma — TERMINATED · PHASE2
• A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer — TERMINATED · PHASE1
• A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges — COMPLETED · PHASE2

Refine this search